Atopic dermatitis (eczema): trials for referral
285 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
285 trials shown
Phase 14 sites
RecruitingSweden
2026-526343-35-00
A double-blind, randomised, placebo-controlled first-in-human/Phase Ib trial to investigate safety, tolerability, pharmacokinetics, and preliminary efficacy of single and multiple doses of TIR-C 2% cutaneous emulsion in adults with mild to moderate atopic dermatitis
Pharmability AB
Registry updated 5 Nov 2026
Registry record: EU CTISPhase 253 sites
RecruitingBulgaria, Canada, China, Czechia, Germany, France
NCT07216027
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
Pfizer
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT07262983
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
National Institute of Allergy and Infectious Diseases (NIAID)
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07919899
Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation
Sanofi
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
Not yet recruitingBrazil
NCT07918560
Cosmetic Efficacy Evaluation of Hydraporin AI Cream in Individuals With Atopic Dermatitis and Psoriasis
Brainfarma Industria Química e Farmacêutica S/A
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 110 sites
RecruitingPoland, United States
NCT06564389
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Pfizer
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT00605878
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
National Human Genome Research Institute (NHGRI)
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 343 sites
RecruitingChina, Germany, Spain, Hungary, Japan, Mexico
NCT06807281
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Pfizer
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT01631617
Effects of Treatments on Atopic Dermatitis
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govNo phase2 sites
Not yet recruitingGermany
NCT07918586
Localized Aeroallergen Exposure in Atopic Dermatitis
Fraunhofer-Institute of Toxicology and Experimental Medicine
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingFrance
NCT07909967
Observational Analytical Validation Study of the Replior ScratchSense
Replior AB
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 114 sites
RecruitingAustralia, China, New Zealand
NCT07235384
A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
Zai Lab (Shanghai) Co., Ltd.
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 31 site
Not yet recruitingUnited States
NCT07916480
Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
Arcutis Biotherapeutics, Inc.
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 35 sites
Not yet recruitingCzechia
2025-525022-35-00
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
Hunan Mabgeek Biotech Co. Ltd.
Registry updated 4 Nov 2026
Registry record: EU CTISNo phase1 site
RecruitingUnited States
NCT04864886
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
National Institute of Allergy and Infectious Diseases (NIAID)
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 12 sites
RecruitingBelgium, United States
NCT07660731
A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma
Pfizer
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 271 sites
RecruitingCanada, Czechia, Germany, Spain, France, United Kingdom
NCT07003425
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Apogee Therapeutics, Inc.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 22 sites
RecruitingTaiwan
NCT07914088
A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis
Arjil Pharmaceuticals LLC
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govNo phase82 sites
RecruitingUnited Arab Emirates, Canada, China, Spain, France, Italy
NCT07290803
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
Sanofi
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT06096857
Cardamom and Topical Roseomonas in Atopic Dermatitis
National Institute of Allergy and Infectious Diseases (NIAID)
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT02504853
Natural History and Genetics of Food Allergy and Related Conditions
National Institute of Allergy and Infectious Diseases (NIAID)
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingGermany
NCT07904546
ADBest TREAT Registry
Universitätsklinikum Hamburg-Eppendorf
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 40 sites
Not yet recruiting
NCT07905547
A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis
Sanofi
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingAustralia
NCT07904689
A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic Dermatitis
North Immunology Inc.
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 29 sites
RecruitingAustralia, New Zealand
NCT07810777
PRA-216 Atopic Dermatitis Safety and Efficacy Study
Prana Therapies Inc
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingCanada
NCT05994976
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
Innovaderm Research Inc.
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 211 sites
RecruitingNorway, Sweden
2025-521620-29-01
Efficacy and safety of two moisturising creams for maintenance treatment of atopic dermatitis
Galenica AB
Registry updated 28 Oct 2026
Registry record: EU CTISPhase 242 sites
RecruitingBulgaria, Czechia, Germany, Spain, Hungary, Poland
2026-525673-39-00
A Phase 2b Study of the Effects of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis
Apollo Therapeutics Limited
Registry updated 28 Oct 2026
Registry record: EU CTISPhase 119 sites
RecruitingAustralia, New Zealand
NCT06934252
Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis
TRex Bio, Inc.
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 217 sites
RecruitingCanada, Ukraine, United States
NCT07782333
A Study Evaluating TRIV-573 in Atopic Dermatitis
Triveni Bio
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States77 open trials
- China59 open trials
- Germany31 open trials
- Poland24 open trials
- France20 open trials
- Spain19 open trials
- Czechia16 open trials
- Italy16 open trials
- Canada15 open trials
- United Kingdom13 open trials
- Australia12 open trials
- Japan11 open trials
- Hungary10 open trials
- Bulgaria9 open trials
- Belgium8 open trials
- Sweden7 open trials
- Denmark7 open trials
- Taiwan6 open trials
- Netherlands6 open trials
- New Zealand5 open trials
- South Korea5 open trials
- Mexico4 open trials
- Switzerland4 open trials
- Finland3 open trials
- Argentina3 open trials
- Singapore3 open trials
- Thailand3 open trials
- Pakistan3 open trials
- Brazil2 open trials
- Saudi Arabia2 open trials
- United Arab Emirates2 open trials
- Portugal2 open trials
- Egypt2 open trials
- Ireland2 open trials
- Norway1 open trials
- Ukraine1 open trials
- Lithuania1 open trials
- Greece1 open trials
- Chile1 open trials
- Slovakia1 open trials
- Latvia1 open trials
- Hong Kong SAR China1 open trials
- Qatar1 open trials
- Croatia1 open trials
- Romania1 open trials
- Russia1 open trials
- Côte d’Ivoire1 open trials
- Mauritius1 open trials
- Mali1 open trials
- Costa Rica1 open trials
- Jordan1 open trials
- Philippines1 open trials
- India1 open trials
- Malaysia1 open trials
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, China
0 trials · 101 publications · ROR
Chinese Academy of Medical Sciences Dermatology Hospital
Nanjing, China
0 trials · 42 publications · ROR
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
2 trials · 32 publications · ROR
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
18 trials · 79 publications · ROR
Hospital General Universitario de Alicante Doctor Balmis
Alicante, Spain
6 trials · 33 publications · ROR
National Institute of Allergy and Infectious Diseases
Bethesda, United States
0 trials · 33 publications · ROR
Rosalind Franklin University of Medicine and Science
North Chicago, United States
0 trials · 88 publications · ROR
The University of Texas Health Science Center at Houston
Houston, United States
3 trials · 41 publications · ROR
The University of Texas Southwestern Medical Center
Dallas, United States
0 trials · 33 publications · ROR
University of California, San Francisco
San Francisco, United States
2 trials · 113 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
New in the registry
Localized Aeroallergen Exposure in Atopic Dermatitis
NCT07918586 · No phase · Germany
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
NCT07873801 · Phase 3 · Germany, Denmark, Spain, France, Poland, Portugal
Source: ClinicalTrials.govOpened for recruitment
NCT07690371 · Phase 3 · Belgium, Bulgaria, Czechia, Spain, Greece, Lithuania
Source: ClinicalTrials.govOpened for recruitment
NCT07711418 · Phase 3 · Czechia, Italy, Latvia, Portugal, United States
Source: ClinicalTrials.govOpened for recruitment
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
NCT07441395 · Phase 2 · Bulgaria, Czechia, Germany, Spain, Italy, Poland
Source: ClinicalTrials.govClosed for recruitment
NCT07223697 · Phase 2 · Brazil, Canada, Germany, Spain, France, Italy
Source: ClinicalTrials.govOpened for recruitment
NCT07037901 · Phase 2 · Australia, Canada, Czechia, Germany, Spain, Hungary
Source: ClinicalTrials.govClosed for recruitment
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
NCT06906497 · Phase 4 · Switzerland, Germany, United States
Source: ClinicalTrials.govOpened for recruitment
NCT06807268 · Phase 3 · China, Germany, Spain, Hungary, Japan, Mexico
Source: ClinicalTrials.govOpened for recruitment
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
NCT06564389 · Phase 1 · Poland, United States
Source: ClinicalTrials.govClosed for recruitment
NCT06461897 · Phase 3 · Argentina, Austria, Australia, Bulgaria, Brazil, Canada
Source: ClinicalTrials.govPhase changed: Phase 4 → Phase 3
NCT06389136 · Phase 3 · Canada, Colombia, Spain, Italy, Japan, South Korea
Source: ClinicalTrials.govOpened for recruitment
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
NCT06239311 · Phase 3 · Czechia, France, Italy, Poland
Source: ClinicalTrials.govClosed for recruitment
NCT06241118 · Phase 3 · United Arab Emirates, Argentina, Australia, Brazil, Canada, Chile
Source: ClinicalTrials.govPhase changed: Phase 4 → Phase 3
NCT05958407 · Phase 3 · Belgium, Canada, Czechia, Germany, Spain, France
Source: ClinicalTrials.govStatus changed: Recruiting → By invitation only
NCT05735483 · Phase 3 · Argentina, Australia, Brazil, Canada, Czechia, Germany
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05509023 · Phase 2 · Poland, United States
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05559359 · Phase 3 · Argentina, Australia, Brazil, Canada, Czechia, Germany
Source: ClinicalTrials.govClosed for recruitment
NCT05492578 · Phase 2/3 · United Arab Emirates, Argentina, Australia, Bulgaria, Brazil, Canada
Source: ClinicalTrials.govClosed for recruitment
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
NCT06239311 · Phase 3 · Czechia, France, Italy, Poland
Source: ClinicalTrials.govOpened for recruitment
NCT05492578 · Phase 2/3 · United Arab Emirates, Argentina, Australia, Bulgaria, Brazil, Canada
Source: ClinicalTrials.govOpened for recruitment
NCT06241118 · Phase 3 · United Arab Emirates, Argentina, Australia, Brazil, Canada, Chile
Source: ClinicalTrials.govOpened for recruitment
NCT06461897 · Phase 3 · Argentina, Austria, Australia, Bulgaria, Brazil, Canada
Source: ClinicalTrials.govClosed for recruitment
NCT06807268 · Phase 3 · China, Germany, Spain, Hungary, Japan, Mexico
Source: ClinicalTrials.govStatus changed: Running, not recruiting → Not yet recruiting
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
NCT06906497 · Phase 4 · Switzerland, Germany, United States
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07037901 · Phase 2 · Australia, Canada, Czechia, Germany, Spain, Hungary
Source: ClinicalTrials.govOpened for recruitment
NCT07223697 · Phase 2 · Brazil, Canada, Germany, Spain, France, Italy
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
NCT06564389 · Phase 1 · Poland, United States
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
NCT07441395 · Phase 2 · Bulgaria, Czechia, Germany, Spain, Italy, Poland
Source: ClinicalTrials.govOpened for recruitment
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
NCT07873801 · Phase 3 · Germany, Denmark, Spain, France, Poland, Portugal
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07711418 · Phase 3 · Czechia, Italy, Latvia, Portugal, United States
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07690371 · Phase 3 · Belgium, Bulgaria, Czechia, Spain, Greece, Lithuania
Source: ClinicalTrials.govStopped early
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06058156 · Phase 2 · Czechia, Germany, Greece, Poland, United States
Source: ClinicalTrials.govNew in the registry
Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
NCT07916480 · Phase 3 · United States
Source: ClinicalTrials.gov
New reviews, guidelines and randomised trials in PubMed
Randomised trial
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · PubMed
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 2Ended 29 Oct 2026
Phase 3Ended 9 Oct 2026
Completed880 participants
NCT02612454
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
- Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis. · Paediatric drugs, 2026
- Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic Dermatitis. · American journal of clinical dermatology, 2026
- Pharmacokinetics, efficacy and safety of dupilumab administered with prefilled pen devices in patients aged <12 years with atopic dermatitis. · British journal of clinical pharmacology, 2026
Phase 4Ended 21 Sept 2026
Completed233 participants
NCT07006792
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
No phaseEnded 2 Sept 2026
Phase 3Ended 31 Aug 2026
Completed1935 participants
NCT03989206
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
Phase 4Ended 27 Aug 2026
Completed256 participants
NCT05642208
Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis
Phase 4Ended 27 Aug 2026
Completed256 participants
2022-501179-23-00
Dupilumab step-down strategy to maintain remission in adult and adolescents patients with atopic dermatitis: a non-inferiority randomized trial
Phase 3Ended 26 Aug 2026
Completed652 participants
NCT06468956
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis
Phase 1Ended 24 Aug 2026
Completed294 participants
NCT07411755
A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection
No phaseEnded 20 Aug 2026
Completed30 participants
NCT07580911
Efficacy and Safety of HA35 Gel for Ultra-Rapid Skin Pruritus Relief
Phase 3Ended 18 Aug 2026
Completed417 participants
NCT06554847
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
Phase 3Ended 17 Aug 2026
Completed360 participants
2024-513289-21-00
Study on the prevention of atopic dermatitis symptoms in children with a high risk of the disease through the regular use of a moisturizing skin cream
Phase 1Ended 13 Aug 2026
Completed48 participants
NCT07205081
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
Phase 1Ended 10 Aug 2026
Completed28 participants
2025-522216-17-00
A multi-part, adaptive, Phase 1, first time in human study in healthy participants and participants with atopic dermatitis (AD) to assess the safety, tolerability, pharmacokinetics (PK) of single ascending (SAD), multiple ascending doses (MAD) and selected dose of SYX-5219 (AD Participants)
Phase 2Ended 3 Aug 2026
Phase 1Ended 27 Jul 2026
Completed48 participants
2025-522635-34-00
A Study to Evaluate the Effect of TRIV-509 on Skin Barrier Function in Patients with Atopic Dermatitis.
Phase 3Ended 16 Jul 2026
Completed301 participants
NCT06280716
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
No phaseEnded 30 Jun 2026
Completed15 participants
NCT07463079
Clinical Evaluation of a Soothing Moisturizing Lotion in Individuals With Atopic Eczema
Phase 1Ended 26 Jun 2026
Completed160 participants
NCT07264335
A Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy Subjects
No phaseEnded 22 Jun 2026
Completed41 participants
NCT06353087
Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)
Phase 3Ended 22 Jun 2026
Completed615 participants
NCT05882877
A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)
Phase 1Ended 18 Jun 2026
Phase 1Ended 11 Jun 2026
Completed108 participants
NCT06787586
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
Phase 1Ended 2 Jun 2026
Phase 1Ended 29 May 2026
Phase 1/2Ended 25 May 2026
Completed128 participants
NCT06324812
Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis
No phaseEnded 25 May 2026
No phaseEnded 24 May 2026
Completed30 participants
NCT07618234
Dermocosmetic Evaluation of Propolis Ointments in Atopic-Prone Dry Skin
Phase 3Ended 22 May 2026
Completed516 participants
NCT03952559
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
No phaseEnded 7 May 2026
No phaseEnded 30 Apr 2026
Phase 2Ended 29 Apr 2026
Completed60 participants
NCT07103174
A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis
Phase 2Ended 29 Apr 2026
Completed28 participants
NCT05388760
Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)
No phaseEnded 29 Apr 2026
Completed40 participants
NCT07072273
A Clinical Trial Evaluating a Probiotic Emollient for the Treatment of Pediatric Atopic Dermatitis
Phase 3Ended 23 Apr 2026
Completed174 participants
NCT05916365
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
No phaseEnded 20 Apr 2026
Completed266 participants
NCT03849716
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)
No phaseEnded 17 Apr 2026
Completed80 participants
NCT07577921
Evaluation of the Efficacy of a Cosmetic Care in Subjects With Moderate to Severe Atopic Dermatitis, Treated by Systemic Treatments
No phaseEnded 14 Apr 2026
Completed305 participants
NCT06099704
Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
No phaseEnded 13 Apr 2026
Completed12343 participants
NCT03936335
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Phase 2Ended 13 Apr 2026
No phaseEnded 10 Apr 2026
Completed50 participants
NCT07744516
Clinical Trial to Evaluate the Efficacy and Safety of an Ozonated Oil in Atopic Dermatitis
Phase 2Ended 10 Apr 2026
Completed168 participants
NCT07158151
A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis
Phase 2Ended 9 Apr 2026
No phaseEnded 9 Apr 2026
Completed40 participants
NCT07098000
The Role of Confocal Microscopy in Estimating Dupilumab Treatment Response for Moderate/Severe Atopic Dermatitis
Phase 1Ended 2 Apr 2026
Completed23 participants
NCT06686628
An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
No phaseEnded 1 Apr 2026
Completed80 participants
NCT06983561
Description of the Population With Moderate to Severe Atopic Dermatitis, Treated by Systemic Treatments and Needs Regarding Emollients
No phaseEnded 31 Mar 2026
Completed40 participants
NCT07670676
The Effects of an L-histidine-Based Supplement, Eczema Topical, and Unscented Soap on Children With Eczema
Phase 2Ended 26 Mar 2026
Phase 1Ended 20 Mar 2026
Phase 3Ended 16 Mar 2026
Completed151 participants
NCT06224192
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis
Phase 3Ended 12 Mar 2026
Phase 3Ended 12 Mar 2026
Completed207 participants
NCT05676242
A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis
Phase 1Ended 11 Mar 2026
Completed44 participants
2025-520514-64-00
Phase 1 study with topical cream RLS-1496 in patients with plaque psoriasis or Eczema
Phase 1Ended 28 Feb 2026
Completed11 participants
NCT07329101
Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis
Phase 1Ended 24 Feb 2026
Completed82 participants
NCT06345404
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
Phase 1Ended 23 Feb 2026
Completed71 participants
NCT06686797
A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults
No phaseEnded 20 Feb 2026
No phaseEnded 10 Feb 2026
Phase 1Ended 3 Feb 2026
No phaseEnded 26 Jan 2026
Not medical advice. fetched 6 Nov 2026